Intest Res.  2019 Jan;17(1):54-62. 10.5217/ir.2018.00096.

Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide populationbased study

• Yen HH
• Weng MT
• Tung CC
• Wang YT
• Chang YT
• Chang CH
• Shieh MJ
• Wong JM
• Wei SC

• KMID: 2438443
• DOI: http://doi.org/10.5217/ir.2018.00096

Abstract

BACKGROUND/AIMS
Incidences of inflammatory bowel disease (IBD), ulcerative colitis (UC), and Crohn's disease (CD), have been increasing in Asia. In this study, we report the relevant clinical characteristics and determined the epidemiological trend of IBD in Taiwan from 2001 to 2015.
METHODS
A retrospective study was conducted to analyze data recorded from January 2001 through December 2015 in the registered database compiled by the National Health Insurance and provided by the Ministry of Health and Welfare, Taiwan.
RESULTS
A total of 3,806 patients with catastrophic IBD illness were registered from 2001 to 2015 in Taiwan (CD, 919; UC, 2,887). The crude incidence of CD increased from 0.17/100,000 in 2001 to 0.47/100,000 in 2015, whereas that of UC increased from 0.54/100,000 in 2001 to 0.95/100,000 in 2015. The prevalence of CD increased from 0.6/100,000 in 2001 to 3.9/100,000 in 2015, whereas that of UC increased from 2.1/100,000 in 2001 to 12.8/100,000 in 2015. The male-to-female ratio in the study sample was 2.19 for CD and 1.62 for UC. The median age of those registered with CD was lower than that of those registered for UC: 38.86 and 44.86 years, respectively. A significantly greater increase in CD incidence rate was identified among 20 to 39-year-old compared with other age groups.
CONCLUSIONS
Using Taiwan's nationwide insurance database, we determined that the number of patients with CD increased more rapidly during the study period than the number of patients with UC, especially among age 20 to 39-year-old, resulting in a decreased UC-to-CD ratio.

Keyword

Crohn disease; Colitis, ulcerative; Incidence; Prevalence; Taiwan

MeSH Terms

Adult
Asia
Colitis, Ulcerative
Crohn Disease
Humans
Incidence
Inflammatory Bowel Diseases*
Insurance
National Health Programs
Prevalence
Retrospective Studies
Taiwan*

Figure

• 

  Fig. 1. Incidence of IBD from 2001 to 2015 in Taiwan.

• 

  Fig. 2. Prevalence of IBD from 2001 to 2015 in Taiwan.

• 

  Fig. 3. Incidence rate ratio of UC to CD over time. Comparisons between stages 3 and 1 and stages 3 and 2 revealed significant differences. No significant difference was observed between stages 1 and 2. aComparison the UC/CD ratio between stages 1, 2, and 3.

• 

  Fig. 4. Incidence of CD from 2001 to 2015 stratified by patient age.

• 

  Fig. 5. Sex ratio (male to female) of patients with IBD in Taiwan from 2001 to 2015.

• 

  Fig. 6. Age distribution of patients with CD and UC from 2001 to 2015 in Taiwan.

• 

  Fig. 7. Temporal trends in the UC-to-CD ratio from populationbased studies in Western and Asian countries. Data Sources: Hong Kong (1981–2014) [12], Canada (1996–2009) [22], Korea (2006–2012) [19], Korea (1986–2005) [13], Denmark (1980–2013) [23], Quebec (2001–2008) [24], the Faroe Islands (1960–2014) [9], Taiwan (2001–2015): present study.

Reference

1. Ng SC, Bernstein CN, Vatn MH, et al. Geographical variability and environmental risk factors in inflammatory bowel disease. Gut. 2013; 62:630–649.

2. Chi KR. Epidemiology: rising in the east. Nature. 2016; 540:S100–S102.

3. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018; 390:2769–2778.

4. Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015; 12:720–727.

5. Wei SC, Lin MH, Tung CC, et al. A nationwide populationbased study of the inflammatory bowel diseases between 1998 and 2008 in Taiwan. BMC Gastroenterol. 2013; 13:166.

6. Ishige T, Tomomasa T, Hatori R, et al. Temporal trend of pediatric inflammatory bowel disease: analysis of national registry data 2004-2013 in Japan. J Pediatr Gastroenterol Nutr. 2017; 65:e80. –e82.

7. Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res. 2016; 14:111–119.

8. Yang H, Li Y, Wu W, et al. The incidence of inflammatory bowel disease in Northern China: a prospective population-based study. PLoS One. 2014; 9:e101296.

9. Hammer T, Nielsen KR, Munkholm P, Burisch J, Lynge E. The Faroese IBD study: incidence of inflammatory bowel diseases across 54 years of population-based data. J Crohns Colitis. 2016; 10:934–942.

10. Fonager K, Sørensen HT, Olsen J. Change in incidence of Crohn’s disease and ulcerative colitis in Denmark: a study based on the national registry of patients, 1981-1992. Int J Epidemiol. 1997; 26:1003–1008.

11. Yoshida Y, Murata Y. Inflammatory bowel disease in Japan: studies of epidemiology and etiopathogenesis. Med Clin North Am. 1990; 74:67–90.

12. Ng SC, Leung WK, Shi HY, et al. Epidemiology of inflammatory bowel disease from 1981 to 2014: results from a territorywide population-based registry in Hong Kong. Inflamm Bowel Dis. 2016; 22:1954–1960.

13. Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis. 2008; 14:542–549.

14. Hilmi I, Jaya F, Chua A, Heng WC, Singh H, Goh KL. A first study on the incidence and prevalence of IBD in Malaysia: results from the Kinta Valley IBD Epidemiology Study. J Crohns Colitis. 2015; 9:404–409.

15. Prideaux L, Kamm MA, De Cruz PP, Chan FK, Ng SC. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol. 2012; 27:1266–1280.

16. Ng SC, Tsoi KK, Kamm MA, et al. Genetics of inflammatory bowel disease in Asia: systematic review and meta-analysis. Inflamm Bowel Dis. 2012; 18:1164–1176.

17. Bernstein CN, Shanahan F. Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut. 2008; 57:1185–1191.

18. Wei SC, Shieh MJ, Chang MC, Chang YT, Wang CY, Wong JM. Long-term follow-up of ulcerative colitis in Taiwan. J Chin Med Assoc. 2012; 75:151–155.

19. Kim HJ, Hann HJ, Hong SN, et al. Incidence and natural course of inflammatory bowel disease in Korea, 2006-2012: a nationwide population-based study. Inflamm Bowel Dis. 2015; 21:623–630.

20. Wei SC, Chang TA, Chao TH, et al. Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease. Intest Res. 2017; 15:266–284.

21. Wei SC, Chang TA, Chao TH, et al. Management of Crohn’s disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease. Intest Res. 2017; 15:285–310.

22. Leddin D, Tamim H, Levy AR. Decreasing incidence of inflammatory bowel disease in eastern Canada: a population database study. BMC Gastroenterol. 2014; 14:140.

23. Lophaven SN, Lynge E, Burisch J. The incidence of inflammatory bowel disease in Denmark 1980-2013: a nationwide cohort study. Aliment Pharmacol Ther. 2017; 45:961–972.

24. Bitton A, Vutcovici M, Patenaude V, Sewitch M, Suissa S, Brassard P. Epidemiology of inflammatory bowel disease in Québec: recent trends. Inflamm Bowel Dis. 2014; 20:1770–1776.

25. Yen HH, Chang CW, Chou JW, Wei SC. Balloon-assisted enteroscopy and capsule endoscopy in suspected small bowel Crohn’s disease. Clin Endosc. 2017; 50:417–423.

26. Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology. 2017; 152:313–321.

27. Chiang TH, Lee YC, Liao WC, et al. Timing and risk factors for a positive fecal immunochemical test in subsequent screening for colorectal neoplasms. PLoS One. 2015; 10:e0136890.

28. van der Valk ME, Mangen MJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study. Gut. 2014; 63:72–79.

29. Wei SC. Differences in the public medical insurance systems for inflammatory bowel disease treatment in Asian countries. Intest Res. 2016; 14:218–223.

30. Chang CW, Wei SC, Chou JW, et al. Safety and efficacy of adalimumab for patients with moderate to severe Crohn’s disease: the Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study. Intest Res. 2014; 12:287–292.

31. Lin WC, Chou JW, Yen HH, et al. Outcomes of limited period of adalimumab treatment in moderate to severe Crohn’s disease patients: Taiwan Society of Inflammatory Bowel Disease Study. Intest Res. 2017; 15:487–494.